Genesis Therapeutics and Eli Lilly entered into a strategic collaboration to discover novel therapies utilizing Genesis’ AI platform.
PharmaLive talked to Gerald Martinetz at Mindbreeze regarding how data is transforming R&D in the metaverse.
Dubbed Cambridge Crossing, Sanofi’s new U.S. facilities set to open during May 2022 will hold the tools to develop innovative drug discovery platforms for chemistry, protein engineering, structural and synthetic biology, among many other key modalities.
Historically, therapies focusing on niche markets face tremendous obstacles, from drug development and clinical trials to drug access. Drew Desjardins – EVP, Chief Strategy Officer, Fishawack Health – analyzes several key challenges for brand marketers readying to launch products in these small markets, along with solutions for driving better stakeholder experiences.
Amgen and Generate Biomedicines inked a research partnership to discover and develop protein therapeutics for five clinical targets.
The popularity of decentralized clinical trials (DCTs) is surging, especially among patients. Harnessing technology of all kinds, these trials provide an attractive alternative to the old-style, site-anchored system on which traditional clinical trials have rested. They also have the potential to provide better, more timely data since that data is primarily collected under real-life situations and often available more quickly to monitoring teams, according to Kristin Mauri, Director of Solution Services, Remarque Systems.
Codagenix Inc. announced favorable safety and immunogenicity data from a Phase I dose-escalation trial of the company’s single-dose intranasal COVI-VAC vaccine, and London-based pHOXBIO Ltd. reported results from a pivotal phase II/III study of the novel prophylactic nasal spray pHOXWELL.
Two very exciting areas where Artificial Intelligence (AI) is having an impact on the life sciences landscape are patient stratification and synthetic control arms. Recent data and technology advances are starting to yield compelling results, according to Derek Baird, President North America of Sensyne Health and Commercial Director of SENSE.
Finding more information about your personal health or the health of your family has never been more meaningful than over the past year. For many individuals, patients and consumers, the need to address myriad questions and seek out additional areas of interest has become a quest. But in an age when information is ubiquitous and public health is top of mind, a new study on health fluency indicates that the road to such insight is now paved with multiple lanes and involves more than the traditional health care organizations and companies relied on before.
In an effort to boost drug discovery for the “toughest drug discovery problems” through the use of machine learning, precision medicines company Relay Therapeutics is acquiring Waltham, Mass.-based ZebiAI with an $85 million upfront payment.